59702-32-8 Usage
Uses
Used in Pharmaceutical Research:
2,3-Piperazinedione,1-propyl-(9CI) is used as a research compound for exploring its potential pharmacological properties and applications in drug development. Its unique structural features, including the piperazinedione core and the propyl group, may offer insights into the design of new therapeutic agents.
Used in Drug Development:
2,3-Piperazinedione,1-propyl-(9CI) is used as a lead compound in the development of new drugs. Its potential biological activities and interactions with biological targets could be harnessed to create novel therapeutics for various medical conditions. Further studies and research are needed to fully understand its properties and potential uses in this field.
Check Digit Verification of cas no
The CAS Registry Mumber 59702-32-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,7,0 and 2 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 59702-32:
(7*5)+(6*9)+(5*7)+(4*0)+(3*2)+(2*3)+(1*2)=138
138 % 10 = 8
So 59702-32-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H12N2O2/c1-2-4-9-5-3-8-6(10)7(9)11/h2-5H2,1H3,(H,8,10)
59702-32-8Relevant academic research and scientific papers
PENICILLIN-BINDING PROTEIN INHIBITORS
-
Paragraph 00249, (2018/12/13)
Described herein are certain boron-containing compounds, compositions, preparations and their use as modulators of the transpeptidase function of bacterial penicillin-binding proteins and as antibacterial agents. In some embodiments, the compounds described herein inhibit penicillin-binding proteins. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
ASPARTYL PROTEASE INHIBITORS
-
Page 226-230, (2010/02/05)
The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.
